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Abstract
Background: Change of first-line treatment of uncomplicated malaria to artemisinin-combination therapy (ACT) is widespread
in Africa. To expand knowledge of safety profiles of ACT, pharmacovigilance activities are included in the implementation
process of therapy changes. Ghana implemented first-line therapy of artesunate-amodiaquine in 2005. Drug utilization data is an
important component of determining drug safety, and this paper describes how anti-malarials were prescribed within a
prospective pharmacovigilance study in Ghana following anti-malarial treatment policy change.
Methods: Patients with diagnosis of uncomplicated malaria were recruited from pharmacies of health facilities throughout
Accra in a cohort-event monitoring study. The main drug utilization outcomes were the relation of patient age, gender, type of
facility attended, mode of diagnosis and concomitant treatments to the anti-malarial regimen prescribed. Logistic regression was
used to predict prescription of nationally recommended first-line therapy and concomitant prescription of antibiotics.
Results: The cohort comprised 2,831 patients. Curative regimens containing an artemisinin derivative were given to 90.8% (n
= 2,574) of patients, although 33% (n = 936) of patients received an artemisinin-based monotherapy. Predictors of first-line
therapy were laboratory-confirmed diagnosis, age >5 years, and attending a government facility. Analgesics and antibiotics were
the most commonly prescribed concomitant medications, with a median of two co-prescriptions per patient (range 1–9).
Patients above 12 years were significantly less likely to have antibiotics co-prescribed than patients under five years; those
prescribed non-artemisinin monotherapies were more likely to receive antibiotics. A dihydroartemisinin-amodiaquine
combination was the most used therapy for children under five years of age (29.0%, n = 177).
Conclusion: This study shows that though first-line therapy recommendations may change, clinical practice may still be affected
by factors other than the decision or ability to diagnose malaria. Age, diagnostic confirmation and suspected concurrent
conditions lead to benefit:risk assessments for individual patients by clinicians as to which anti-malarial treatment to prescribe.
This has implications for adherence to policy changes aiming to implement effective use of ACT. These results should inform
education of health professionals and rational drug use policies to reduce poly-pharmacy, and also suggest a potential positive
impact of increased access to testing for malaria both within health facilities and in homes.
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Background
Artemisinin combination therapy (ACT) is becoming
first-line treatment for uncomplicated Plasmodium falci-
parum malaria episodes throughout Africa. The urgency
for ACT roll-out was spurred by alarming levels of drug
resistance to previously used monotherapies such as chlo-
roquine and sulphadoxine-pyrimethamine (SP) and ris-
ing morbidity and mortality [1,2]. Kwa-Zulu Natal was
the first health ministry to switch to an ACT in 2001 [3],
and ACT have now been adopted in 28 African countries,
with an additional 13 in the process of implementation
[4]. In Ghana, the Ministry of Health (MOH) policy
changed, in 2004, in line with World Health Organization
(WHO) recommendations to artesunate plus amodi-
aquine (ART-AQ) as first-line therapy for uncomplicated
malaria from 1st January 2005 [5]. Reports of adverse
events with ART-AQ received by the then National Centre
for Pharmacovigilance at the University of Ghana Medical
School (UGMS) and increasing negative media coverage
on the safety of ART-AQ led to withdrawal of specified
brands of ART-AQ in December 2005 [6]. This was accom-
panied by a fall in the number of reports though there had
been 131 reports of adverse events (AEs) to ART-AQ to the
UGMS by October 2007 [7].
Active post-marketing drug safety surveillance using pre-
scription-event monitoring methodology is practiced
both in the UK [8] and New Zealand [9] by collecting
event information for patients prescribed new drugs to
detect previously unknown drug effects or to better char-
acterize known effects in 'real-life'. Within the context of
post-marketing monitoring for adverse events, a knowl-
edge of the patterns of drug utilization, both in terms of
prescriber characteristics and patient population, are
essential to characterize the potential risks that patients
may experience. In March 2006, a non-interventional
pharmacovigilance study was initiated in Accra to comple-
ment the spontaneous reporting system for newly intro-
duced anti-malarials. The study was originally designed to
compare the 'real-life' safety profiles of ART-AQ and chlo-
rproguanil-dapsone (LapDap™) as they are used in real-
life settings in Ghana. However, due to the limited use of
LapDap™ following introduction of ACT [10] and the
progress of the development of chlorproguanil-dapsone-
artesunate [11], data on the existing available anti-malar-
ial regimens was collected though the concerns above
caused the study to be formally terminated by the spon-
sor, WHO-TDR, in November 2006.
The objective of this paper is to describe the mode of diag-
nosis and pattern of drug management in outpatients
diagnosed with suspected uncomplicated malaria in
health facilities in Accra, Ghana who were recruited into a
prospective pharmacovigilance study. Safety analysis of
adverse events experienced during treatment with the
anti-malarials reported in the cohort will be presented in
a forthcoming paper.
Methods
Data presented in this article were collected during a pro-
spective, longitudinal, non-interventional study to moni-
tor adverse events (AEs) following administration of anti-
malarials for uncomplicated malaria in Accra, the capital
city of Ghana.
Study design and sample size
A cohort-event monitoring methodology was used, in
which all new patients prescribed anti-malarials for
uncomplicated malaria, in the normal course of medical
practice in the participating healthcare facilities in Accra
were eligible for recruitment; patients with severe/compli-
cated malaria and pregnant women were excluded. An
urban area was chosen to be able to recruit a large cohort
in a short time period, and to reduce logistical constraints
of follow-up as many people were contactable by tele-
phone and lived nearby to facilitate home visits. The vari-
ety of health facilities and large numbers of health
professionals enabled assessment of a wide range of prac-
tices. The average prevalence of malaria in children in
Accra is estimated at 14.8%, ranging from 6% to 22% by
community [12]. The sample size calculation for the orig-
inal study was based on the possibility of detecting a rare
adverse event at a frequency of 1 in 3,000 patients – that
is a sample size of 10,000 patients for each drug [13].
Although the study was discontinued prematurely by the
sponsor, a substantial number of patients had already
been included in the cohort.
Recruitment
All public health facilities in Accra were approached to
participate in the study and agreed to take part. Private
facilities with adequate staff availability and patient load
were also invited to participate. The 24 health institutions
who participated are thought to be representative of prac-
tice across Accra; 15 government hospitals/clinics, two
quasi-government hospitals, one private clinic and six
community pharmacies. Each facility was asked to sign a
consent form to indicate acceptance for participation. All
facilities operate a 'fee for service' system and fees are very
similar across facility types. Eligible patients were
recruited consecutively from the pharmacy at the time of
dispensing the drug in order to reduce the number of
patients who might be prescribed anti-malarials but who
may be unable to obtain their supplies either due to avail-
ability of medicines or lack of patient funds. Patient
recruitment rates varied based on staff time and the ability
of research team to post dedicated data collectors to the
sites.Malaria Journal 2009, 8:2 http://www.malariajournal.com/content/8/1/2
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Data collection
Data collected on the day of anti-malarial dispensing
included demographics, contact details, method of diag-
nosis (health professional presumptive diagnosis [by type
of health professional] or slide-confirmed), anti-malarial
drugs prescribed and concomitant medications dispensed
on that day. All recruited patients were given a study card
which they could present at the Out-Patients Department
of the Korle-Bu Polyclinic (affiliated to the teaching hos-
pital) in case their clinical condition did not improve and
they were unable or unwilling to visit a primary care facil-
ity or in case of adverse events for which the patient
wished to seek hospital treatment. Collection of adverse
event data by systematic follow-up contact by the research
team and use of spontaneous report forms by patients will
be discussed in a subsequent paper.
Data management and analysis
Each enrolled patient was given a unique study number
that was used in the storage and management of all data
relating to the patient. Data were double entered, data
cleaned and managed using Microsoft Access (Microsoft
Corporation, Redmond, Washington) and analysed using
STATA version 9.2, (Stata Corporation, College Station,
Texas). Anti-malarial treatment groups were defined as
follows: i) recommended first-line therapy (artesunate
plus amodiaquine – ART-AQ); ii) 'other ACT' group –
patients taking an artemisinin derivative in combination
with a non-artemisinin-containing anti-malarial; iii)
monotherapy (artemisinin) group – patients taking only
artemisinin-based compounds for treatment of malaria
episode, including more than one type of artemisinin e.g.
artemether injection followed by oral artesunate; iv) mon-
otherapy (other) group – other monotherapy regimens
not containing artemisinin compounds. Data was
expressed as means and standard deviations (SD) for con-
tinuous variables, and frequencies and percentages for cat-
egorical variables. Categories of the variable 'facility type'
were regrouped into government facilities vs. non-govern-
ment facilities (quasi-government, private clinic, commu-
nity pharmacy) due to small numbers and common
characteristics within the non-government group. Catego-
ries of the variable 'mode of diagnosis' were regrouped
into laboratory confirmed diagnosis vs. presumptive diag-
nosis (including doctor, pharmacist, other health profes-
sional and self) categories. Chi-square and Fishers' Exact
Test were used for categorical variables and students T-test
for continuous variables for univariate analysis to predict
prescription of: i) first-line therapy (ART-AQ); ii) antibiot-
ics. Results were considered statistically significant at a
level of p < 0.05.
A stepwise multivariate logistic regression method was
used to assess the effect of variables on the outcomes of
prescription of first line therapy and antibiotics using a
significance level for entry of the variable/category into
the model of p = 0.15. The performance of the model was
assessed on calibration and discrimination using Hosmer-
Lemeshow goodness-of-fit test and area under the
Receiver Operating Characteristic (ROC) curve respec-
tively. 'Discrimination' refers to a variable's ability to dis-
tinguish prescription of first line therapy/antibiotic use
from no prescription of first line therapy/no antibiotic
use. The AUC represents the probability that a patient
who had ART-AQ or used antibiotics had a higher pre-
dicted probability than those who did not. An AUC of 0.5
indicates that the variables do not predict better than
chance. The discrimination of the variables is considered
perfect if AUC = 1, good if AUC >0.8, moderate if AUC is
0.6 to 0.8, and poor if AUC <0.6. 'Calibration' refers to the
agreement between predicted probabilities and the 'true
probabilities', which can be approximated by taking the
mean of the observed outcomes within predefined groups
of patients. The Hosmer-Lemeshow test compares the
observed outcome in a group with the predicted outcome
of that group [14]. The C goodness-of-fit statistic sorts
observations according to their expected probability and
partitions the observations into ten groups of equal size.
A high H relates to a small p value, implying significant
difference between observed and predicted outcome, and
thus indicates a lack of fit of the variables.
Ethical approval
Ethical approval for the project was obtained from the
Ethical and Protocol Review Committee of the University
of Ghana Medical School. The original protocol was also
approved by WHO/TDR internal ethical procedures. Par-
ticipation for patients was subject to a signed and wit-
nessed informed consent form by the patient or his/her
carer or guardian for children (under 18 years).
Results
Recruitment was carried out between April 2006 and
November 2006. Of patients who were diagnosed with
malaria and attended pharmacies to collect medication,
more than 95% consented to participate. The most com-
mon reason for non-participation was time constraints for
the patient. The final number of patients recruited was
2,835, although four of these were excluded from analysis
due to ambiguity of anti-malarial prescribed. The majority
of patients were recruited from government facilities
(95.9%, n = 2,716).
Cohort characteristics and malaria diagnosis
60.6% of the cohort was in the 13–59 year age band
(Table 1). Although overall females comprised 59.9% of
the cohort, the proportion of females increased with
increasing age, from 48.4% of under 5's to 69.4% of the
over 60's (Chi square trend for those with known age =
63.6, p < 0.001). The major mode of diagnosis of malariaMalaria Journal 2009, 8:2 http://www.malariajournal.com/content/8/1/2
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was presumptive diagnosis by a physician (Table 1). Only
3.2% (n = 91) of diagnoses were parasitologically con-
firmed, with the highest proportion of laboratory con-
firmed diagnoses in the 5–12 years age group (6.0%, n =
19).
Anti-malarial treatment prescribed
There were 23 different anti-malarial regimens recorded
(Table 2). The majority of patients (90.8%) received an
artemisinin-based compound in their treatment regimen.
However, only 43.0% received the recommended first line
therapy of ART-AQ, although this was the most common
regimen reported. Dihydroartemisinin (DHA) was used
next most frequently, either alone (20.4%) or combined
with another anti-malarial (9.4%). The proportion of
patients according to characteristic who were prescribed
ART-AQ as opposed to the other regimens is shown in
Table 3, with logistic regression results in Table 4. It is of
note that of the 91 microscopically confirmed diagnoses,
86.8% (n = 79) were prescribed ART-AQ (adjusted OR 9.7
[5.2–18.2]). Other factors related to ART-AQ prescription
were patients aged five years or above and attendance of a
government facility. The goodness of fit test for the regres-
sion model had a Hosmer-Lemeshow chi square value=
0.07, (2 degrees of freedom), p-value = 0.97. The area
under the ROC curve was 0.63 indicating a moderate fit of
the model.
Co-prescribed medications
Co-prescribed medications were given to 89.5% of the
cohort (n = 2,533), with a median number of two per
patient (range 1–9). The most commonly prescribed con-
comitant medications were analgesics, given to 76.3% (n
= 2,162) of patients, followed by antibiotics (30.8%, n =
872), and vitamins (25.8%, n = 729). The proportion of
patients according to characteristic who were prescribed
antibiotics and logistic regression results are in Tables 3
and 4 respectively. Patients aged over 12 years were signif-
icantly less likely to have an antibiotic co-prescription
than patients under 5 years, while patients prescribed
non-artemisinin monotherapies were significantly more
likely to have anti-biotic co-prescription. The Hosmer-
Lemeshow goodness of fit test had a chi-square of 4.85,
(df = 3), p-value = 0.18, indicating good fit. However, the
area under the ROC curve was poor with an AUC = 0.58.
Table 1: Characteristics according to age group
Age group Total
<5 5–12 13–59 ≥60 NK
n = 610
(21.6%)
n = 317
(11.2%)
n = 1,716
(60.6%)
n = 157
(5.5%)
n = 31
(1.1%)
N = 2,831
n (%) n (%) n (%) n (%) n (%) n (%)
Gender
Male 315 (51.6) 151 (47.6) 606 (35.3) 48 (30.6) 16 (51.6) 1,136 (40.1)
Female 295 (48.4) 166 (52.4) 1,110 (64.7) 109 (69.4) 15 (48.4) 1,695 (59.9)
Facility type
Community pharmacy 4 (0.7) 1 (0.3) 18 (1.1) 3 (1.9) 0 (0) 26 (0.9)
Government 599 (98.2) 312 (98.4) 1,621 (94.5) 153 (97.5) 31 (100) 2,716 (95.9)
Private clinic 4 (0.7) 1 (0.3) 27 (1.6) 0 (0) 0 (0) 32 (1.1)
Quasi-government 3 (0.5) 3 (1.0) 50 (2.9) 1 (0.6) 0 (0) 57 (2.0)
Mode of diagnosis
Doctor 501 (82.1) 242 (76.4) 1,383 (80.6) 125 (79.6) 18 (58.1) 2,269 (80.2)
Laboratory Confirmation 20 (3.3) 19 (6.0) 48 (2.8) 3 (1.9) 1 (3.2) 91 (3.2)
Other health professional 18 (3.0) 22 (6.9) 127 (7.4) 8 (5.1) 5 (16.1) 180 (6.4)
Pharmacist 0 (0) 0 (0) 10 (0.6) 1 (0.6) 0 (0) 11 (0.4)
Self 0 (0) 2 (0.6) 6 (0.4) 0 (0) 0(0) 8 (0.3)
Unknown 71 (11.6) 32 (10.1) 142 (8.3) 20 (12.7) 7 (22.6) 272 (9.6)
Anti-malarial treatment prescribed
Combination therapy
(ART-AQ)
161 (26.4) 181 (57.1) 790 (46.0) 76 (48.4) 9 (29.0) 1,217 (43.0)
Combination therapy
(Other ACT)
240 (39.3) 40 (12.6) 124 (7.2) 5 (3.2) 9 (29.0) 418 (14.8)
Monotherapy
(Artemisinin based)
111 (18.2) 55 (17.4) 700 (40.8) 61 (38.9) 9 (29.0) 936 (33.1)
Monotherapy
(Non-artemisinin)
98 (16.1) 41 (12.9) 102 (5.9) 15 (9.6) 4 (12.9) 260 (9.2)
NK = not knownMalaria Journal 2009, 8:2 http://www.malariajournal.com/content/8/1/2
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Children under five years
There were 610 patients aged under five years in the
cohort and this age group was more likely to be prescribed
a DHA-AQ combination (29%, n = 177), rather than ART-
AQ (26.4%, n = 161). Amodiaquine and DHA were used
as monotherapies in a further 15.7% (n = 96) and 13.8%
(n = 84) respectively. Only two children under five years
received a non-artemisinin monotherapy (chloroquine).
Under-fives were the most likely to receive an antibiotic
(42.6%, n = 260), and the least likely to receive an analge-
sic (60.8%, n = 371) or a vitamin (15.4%, n = 94).
Discussion
This evaluation, including predominantly government
facilities in an urban setting, showed that nearly two years
following the change in national anti-malarial policy, the
first-line therapy was adhered to in less than 50% of cases.
It is possible that the initial safety concerns associated
with ART-AQ and availability of a wide variety of alterna-
tives in addition to the fact that patients pay at the point
of service delivery could have contributed to this. Artem-
isinins, either as monotherapy or combination therapy,
were used to treat more than 90% of cases of uncompli-
cated malaria, indicating widespread acceptance of artem-
isinin therapies and their extensive absorption into urban
health facilities. However, 33.1% of patients received an
artemisinin monotherapy, a regimen which has not been
recommended by WHO since January 2006 due to the
potential for drug resistance in this class of drugs due to its
short half-life. The reasons for this may include lack of
availability of ACTs or safety concerns of the prescriber
following the media coverage of side effects of amodi-
aquine. The need to educate health care workers to stop
recommending artemisinin monotherapy is obvious and
urgent. This situation could be expected to be different in
rural areas, where there is less choice of drugs and where
subsidized ART-AQ is available in health centres. The
diversity of regimens used has implications for post-mar-
keting safety monitoring, where correct ascertainment of
exposure is necessary for attribution of potential adverse
effects to a specific suspect drug.
This study illustrated some practical realities of the day-to-
day diagnosis and treatment of uncomplicated malaria.
Firstly, the high level of presumptive diagnosis of malaria,
based on country-specific guidelines [5], seems to be a
limiting factor for prescribing the new first-line therapy. A
patient with a parasitologically confirmed diagnosis was 9
times more likely than a patient with presumptive diagno-
sis to be prescribed the first-line therapy, suggesting that
the confidence of health professionals in adhering to new
guidelines is enhanced by having access to confirmatory
tests. Similar findings in Zambia where the first-line ther-
apy artemether-lumefantrine was prescribed more fre-
quently to patients with positive blood smears or rapid
diagnostic tests (RDTs) relative to those with a negative
test would support this [15]. Overall, only 3.2% of the
cohort had a positive test result, indicating very low rates
of use of malaria diagnostics. This would support calls to
roll-out newer diagnostic technologies such as rapid diag-
nostic tests (RDTs) for malaria in conjunction with
changes to ACT first line therapy to limit over-use of ACTs
[16].
Secondly, there was a high level of co-prescription of anti-
biotics (30.8% of patients receiving at least one antibiotic
prescription), which is promoted under febrile illness
strategies [17]. The widespread concomitant use of antibi-
otics has implications for patient safety in increasing the
potential for drug-drug interactions, and also for pharma-
covigilance, as antibiotics have a high incidence of com-
mon adverse events such as rashes and pruritis, which
may be ascribed to the new anti-malarials by patients/
health care providers. The fact that non-artemisinin mon-
otherapy was significantly more likely to be prescribed
with an antibiotic would suggest that these are patients for
whom the prescriber is less confident of a true diagnosis
of malaria and is prescribing anti-malarials as a 'cover' for
potential infection or to prevent subclinical infection
becoming manifest. This correlates with findings in Tan-
Table 2: Anti-malarial treatment prescribed
Drug group/treatment N %
1st line therapy (ART-AQ) 1,217 43.0
Combination therapy – other ACT 418 14.8
DHA+AQ 240 8.5
Artemether+AQ 77 2.7
Artemether+lumefantrine 58 2.1
DHA+pyrimethamine-sulphametopirazine 13 0.5
Artesunate+SP 12 0.4
DHA+SP 6 0.2
DHA+chloroquine 5 0.2
Artesunate+chloroquine 3 0.1
Artemether+pyrimethamine-sulphametopirazine 1 0.04
Artemether+quinine 1 0.04
Artesunate+ quinine 1 0.04
DHA+artemether+lumefantrine 1 0.04
Monotherapy – artemisinin based 936 33.1
DHA 577 20.4
Artesunate 293 10.4
Artemether 55 1.9
Artesunate/artemether 10 0.4
Artemether/DHA 1 0.04
Monotherapy – non-artemisinin 260 9.2
Amodiaquine 133 4.7
SP 78 2.8
Pyrimethamine-sulphametopirazine 32 1.1
Chloroquine 14 0.5
Quinine 3 0.1
Total 2,831
DHA = dihydroartemisinine; AQ = amodiaquine; SP = sulphadoxine-
pyrimethamineMalaria Journal 2009, 8:2 http://www.malariajournal.com/content/8/1/2
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zania for patients with a history of cough within the pre-
vious 48 hours and a negative blood slide being predictive
of no anti-malarial treatment given (as opposed to pre-
scribing anti-malarials even with a negative result) [18].
The benefit:risk decision of the clinician whether or not to
co-prescribe could also depend on factors such as pres-
ence of measurable fever, ability of the patient to afford
the multiple medications, likelihood of the patient being
able to return if the condition worsens and previous treat-
ments the patient received.
Although the under-5 age group were the least likely
group to receive the recommended ART-AQ regimen
(29.0%), this age group seemed to be managed the least
conservatively overall, with only 2 patients receiving chlo-
roquine and no sulphonamides prescribed, and a signifi-
cantly higher proportion of antibiotic prescriptions.
Similar findings have been shown in Zambia and Kenya,
where 11% and 26% of children were prescribed the rec-
ommended ACT shortly after implementation [19,20].
The preference for the DHA-AQ over ART-AQ may reflect
clinician expectation of drug efficacy and/or safety in this
population more likely to have higher parasitaemias and
severe morbidity, the types of paediatric formulations
available or the promotional activities of pharmaceutical
companies operating in Accra. A qualitative study would
be useful to explore this.
There were several potential limitations to this study.
Recruitment was potentially biased towards facilities with
a high patient load, which were mainly government facil-
ities. However, this usage of facilities reflects the health-
seeking behaviour of patients, and is therefore likely to be
a representative sample of the population with suspected
malaria in Accra. Utilization of government health facili-
ties far outstrips that of private facilities, most of which are
small. Other background data on presentation was not
collected and this information could have been useful in
understanding the treatment regimen prescribed, for
example presence of fever on examination, suspected con-
comitant infections and previous intake of anti-malarials.
Drug availability in facilities was not monitored, but
stock-outs highly unlikely due to the multiplicity of prod-
ucts available for purchase by all facilities, both public
and private. This study was purely non-interventional and
did not assess whether prescription was appropriate for
Table 3: Characteristics of patients prescribed first-line therapy (ART-AQ) or a co-prescription of antibiotics
Anti-malarial prescribed Antibiotic co-prescription
ART-AQ Other anti-malarial regimen Antibiotic co-prescription No antibiotic
N = 1,217 N = 1,614 N = 872 N = 1,959
n, %1 n, % n, % n, %
Gender
Male 464 40.9 672 59.2 376 33.1 760 66.9
Female 753 44.4 942 55.6 496 29.3 1,199 70.7
Age group
<5 161 26.4 449 73.6 260 42.6 350 57.4
5–12 181 56.9 136 43.1 119 37.4 198 62.5
13–59 790 46.0 926 54.0 445 25.9 1, 271 74.1
≥60 76 48.4 81 51.6 40 25.5 117 74.5
Not known 9 29.0 22 71.0 8 25.8 23 74.2
Facility type
Non-government 15 13.0 100 87.0 28 24.4 87 75.7
Government 1,202 44.3 1,514 55.7 844 31.1 1,872 68.9
Mode of diagnosis
Presumptive 1,041 42.2 1,427 57.8 758 30.7 1,710 69.3
Laboratory confirmed 79 86.8 12 13.2 21 23.1 70 76.9
Not known 97 35.7 175 64.3 93 34.2 179 65.8
Anti-malarial treatment prescribed
Combination therapy (ART-AQ) - - 349 28.7 868 71.3
Combination therapy (Other ACT) - - 140 33.5 278 66.5
Monotherapy (Artemisinin based) - - 277 29.6 659 70.4
Monotherapy (Non-artemisinin) - - 106 40.8 154 59.2
1 % are row percentages within supercolumnsMalaria Journal 2009, 8:2 http://www.malariajournal.com/content/8/1/2
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age and weight. There was also no information collected
on the availability of diagnostics, which may have
explained the low utilization, although this is more likely
to be due to high patient load and lack of time to wait for
the result. Finally, the level of training of staff or familiar-
ity with guidelines was not assessed as a potential factor
contributing to the variance in prescribing, but as the
majority of facilities were government facilities in the cap-
ital city, these staff would have had the highest likelihood
of access to training and related resources.
In summary, this study further adds support to the state-
ment that global eradication of malaria, as called for by
Bill and Melinda Gates in October 2007 and supported by
WHO, the US President's Malaria Initiative and all major
players [21], is unlikely unless there is proper diagnosis
and management of malaria in all health facilities, includ-
ing those in resource-constrained environments. This
study suggests an important role for confirmatory diag-
nostics in rational prescribing, which would add support
for increased access to diagnostic tools to positively
impact on patient management. Continued education of
government and private providers on the new national
anti-malarial guidelines is also recommended. Knowledge
of drug utilization patterns is key in understanding
patient management and consequent drug safety issues,
and this paper demonstrates the potential difficulties of
pharmacovigilance activities for a recommended first-line
therapy in an environment in which a wide variety of cur-
ative regimens are used. The challenge of pharmacovigi-
lance in environments with limited routine data
collection facilities should not be underestimated and
requires significant innovation.
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Table 4: Predictors of first-line therapy prescription and co-prescription of concomitant antibiotics1,2
Prescription of first-line therapy (ART-AQ) Antibiotic use
Adjusted odds ratio
[95% CI]
p-value Adjusted odds ratio
[95% CI]
p-value
Age group
<5 1.0 1.0
5–12 3.6 [2.6–4.9] <0.001 - -
13–59 2.5 [2.0–3.1] <0.001 0.53 [0.44–0.64] <0.001
≥60 2.6 [1.8–3.9] <0.001 0.55 [0.37–0.83] 0.004
Facility type
Non-government 1.0 - -
Government 6.3 [3.6–11.1] <0.001 - -
Mode of diagnosis
Presumptive 1.0 1.0
Laboratory confirmed 9.7 [5.2–18.2] <0.001 0.68 [0.41–1.1] 0.13
Anti-malarial treatment prescribed
Combination therapy (ART-AQ) - - 1.0
Combination therapy (Other ACT) - - - -
Monotherapy (Artemisinin based) - - 1.2 [0.97–1.4] 0.11
Monotherapy (Non-artemisinin) - - 1.4 [1.1–1.9] 0.02
1 Gender was not significant in either of the final models
2 N = 2,535 for both models. Patients with unknown age (n = 31) and/or unknown mode of diagnosis (n = 272) were excluded.Publish with BioMed Central    and   every 
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